Category: Press Releases

Genprex To Present At The Singular Research Summer Solstice 2018 Conference

NEW YORK, July 18, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that Rodney Varner, Chairman and Chief Executive Officer, will present

Read More

Genprex Selects 4Clinics To Provide Clinical And Regulatory Support For Oncoprex Development Program

AUSTIN, Texas AND CAMBRIDGE, Mass., June 26, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has selected 4Clinics Group Sprl to provide support for the clinical development

Read More

Genprex Engages WIRB-Copernicus Group, Inc. To Provide Clinical Trial Services To Support Oncoprex Clinical Trial Program

AUSTIN, Texas, May 31, 2018 /PRNewswire/ -- Genprex, Inc. (Nasdaq: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it entered into a Master Services Agreement with WIRB-Copernicus Group, Inc. ("WCG")

Read More

Genprex (Nasdaq: GNPX) To Ring The Nasdaq Stock Market Closing Bell

AUSTIN, Texas, May 29, 2018 /PRNewswire/ -- Genprex, Inc. (Nasdaq: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, announced today that its management team will ring the Nasdaq stock market closing bell on Thursday, May 31, 2018

Read More

Genprex To Present At Upcoming Investor And Industry Conferences

AUSTIN, Texas and CAMBRIDGE, Mass., May 23, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that the management team will present

Read More

Genprex Selects Accenture To Support Acceleration Of Oncoprex Clinical Development Program

AUSTIN, Texas and CAMBRIDGE, Mass., May 8, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has selected Accenture to provide clinical data management services to help accelerate

Read More

Genprex Announces $10 Million Private Placement

AUSTIN, Texas, May 7, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has entered into definitive securities purchase agreements with institutional investors

Read More

Genprex To Present At 2018 Disruptive Growth & Healthcare Conference

AUSTIN, Texas, May 7, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that Rodney Varner, Chairman and CEO, will present at the 2018 Disruptive Growth & Healthcare Conference

Read More

Genprex Expands Operations to Cambridge, Mass

CAMBRIDGE, MA / ACCESSWIRE / April 25, 2018 / Genprex, Inc.(NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has established offices in Cambridge, Mass.

Read More

Genprex Joins The Health Discovery Building At Dell Medical School To Help Drive Innovation For Health And Life Sciences

AUSTIN, Texas, April 18, 2018 /PRNewswire/ -- Genprex, Inc., a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today that it has entered an agreement with The University of Texas at Austin Dell Medical School

Read More